These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 17314058

  • 1. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
    Taboada GF, Correa LL, de Oliveira Machado E, van Haute FR, Casini AF, Balarini GA, Neto LV, Calixto L, Calixto C, Gadelha MR.
    Growth Horm IGF Res; 2007 Feb; 17(1):77-81. PubMed ID: 17314058
    [Abstract] [Full Text] [Related]

  • 2. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 3. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 4. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [Abstract] [Full Text] [Related]

  • 5. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE, Thornton-Jones VA, Wass JA.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [Abstract] [Full Text] [Related]

  • 6. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients.
    Resmini E, Barreca A, Ferone D, Giusti M, Sidoti M, Minuto F.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):294-7. PubMed ID: 16117816
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA, Wu Z, Silva CM, Barbosa FR, Dias JS, Schrank Y, Strasburger CJ, Gadelha MR.
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [Abstract] [Full Text] [Related]

  • 8. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 9. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA, Miell JP, Chambers SM, McGregor AM, Aylwin SJ.
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [Abstract] [Full Text] [Related]

  • 10. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [Abstract] [Full Text] [Related]

  • 11. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F.
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [Abstract] [Full Text] [Related]

  • 12. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS.
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [Abstract] [Full Text] [Related]

  • 13. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients.
    Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, Puig-Domingo M.
    Horm Metab Res; 2008 Jun; 40(6):422-6. PubMed ID: 18393173
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
    Bałdys-Waligórska A, Gołkowski F, Krzentowska A, Sokołowski G, Hubalewska-Dydejczyk A.
    Przegl Lek; 2009 Jun; 66(5):218-21. PubMed ID: 19739577
    [Abstract] [Full Text] [Related]

  • 15. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
    Esposito V, Esposito D, Lo Iudice G.
    Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
    [Abstract] [Full Text] [Related]

  • 16. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
    Dohán O, Góth M, Szabolcs I, Kovács L, Kovács Z, Szilágyi G.
    Orv Hetil; 1993 Oct 17; 134(42):2301-3. PubMed ID: 8233444
    [Abstract] [Full Text] [Related]

  • 17. Homocysteine levels in acromegaly patients.
    Hekimsoy Z, Ozmen B, Ulusoy S.
    Neuro Endocrinol Lett; 2005 Dec 17; 26(6):811-4. PubMed ID: 16380700
    [Abstract] [Full Text] [Related]

  • 18. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
    Lorcy Y, Dejager S, Chanson P, French Octreotide LAR Group.
    Pituitary; 2000 Nov 17; 3(3):193-7. PubMed ID: 11383486
    [Abstract] [Full Text] [Related]

  • 19. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
    Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernández I, Molina M, Mercado M.
    Clin Endocrinol (Oxf); 2006 Mar 17; 64(3):245-9. PubMed ID: 16487431
    [Abstract] [Full Text] [Related]

  • 20. [Usefulness of GH and IGF-1 to establish the dose and frequency of application of octreotide to treat acromegaly].
    Martínez-Delgado IA, Gómez-Martínez G.
    Rev Med Inst Mex Seguro Soc; 2007 Mar 17; 45(3):291-5. PubMed ID: 17692168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.